Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-1.23%
SPX
-1.60%
IXIC
-2.24%
FTSE
-0.70%
N225
-0.66%
AXJO
-0.92%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Analysts think ATAI stock price could increase by 288%

Jul 09, 2025, 11:25 AM
58.56%
What does ATAI do
ATAI Life Sciences NV, a Berlin-based clinical-stage biopharmaceutical company, focuses on developing treatments for mental health disorders and went public on June 18, 2021. Key compounds include PCN-101 for treatment-resistant depression and DMX-1002 for opioid use disorder.
7 analysts think ATAI stock price will increase by 287.83%. The current median analyst target is $10.20 compared to a current stock price of $2.63. The lowest analysts target is $5.05 and the highest analyst target is $12.60.
📡️ Health Care
Price Target

More Signals

Feature in Progress
This section is under development. Check back soon for updates!